Telaprevir is a potential drug for repurposing against SARS-CoV-2: computational and in vitro studies.

ABSTRACT: Drug repurposing is an important approach to the assignment of already approved drugs for new indications. This technique bypasses some steps in the traditional drug approval system, which saves time and lives in the case of pandemics. Direct acting antivirals (DAAs) have repeatedly repurposed from treating one virus to another. In this study, 16 FDA-approved hepatitis C virus (HCV) DAA drugs were studied to explore their activities against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) human and viral targets. Among the 16 HCV DAA drugs, telaprevir has shown the best in silico evidence to work on both indirect human targets (cathepsin L [CTSL] and human angiotensin-converting enzyme 2 [hACE2] receptor) and direct viral targets (main protease [M^pro]).

SUBMITTER: Mahmoud A 

PROVIDER: S-EPMC8426143 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature